Scholarlink

Background <p>Impaired central neuropeptide production is implicated in polycystic ovary syndrome (PCOS).</p> Aim <p>This study aimed to determine whether plasma phoenixin-14, galanin (GAL), galanin-like peptide (GALP), and spexin levels in women with PCOS were altered compared to those in non-PCOS controls.</p> Methods <p>Sixty participants, including 30 patients diagnosed with PCOS and 30 healthy controls, were enrolled in this study. Phoenixin-14, GAL, GALP, and spexin levels were measured in plasma samples.</p> Results <p>Although plasma phoenixin-14 levels in the PCOS group were significantly higher than those in the control group, spexin and GAL levels were significantly lower. No significant intergroup differences were observed in plasma GALP levels (<i>p</i> = 0.442). To distinguish PCOS from healthy controls, the area under the receiver operating characteristic (ROC)&#xa0;curve (AUC) of phoenixin-14 was 0.798, that of spexin was 0.757, and that of GAL was 0.702 (<i>p</i> &lt; 0.001, <i>p</i> &lt; 0.001, and <i>p</i> = 0.003, respectively). The AUC of the combined diagnostic value of the three peptides for PCOS was 0.910 (95%CI: 0.808–0.968) (<i>p</i> &lt; 0.001), indicating a good diagnostic value.</p> Conclusions <p>Plasma phoenixin-14, spexin, and GAL levels differed between patients with PCOS and controls. When combined, the three peptides exhibited better predictive performance than the individual peptides.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating plasma phoenixin-14, galanin, galanin-like peptide, and spexin levels in polycystic ovary syndrome

  • 期刊论文

  • 发表日期：

    2025年9月24日

查看全文
  • Meltem Yardim,
  • Huseyin Fatih Gul,
  • Ulku Ayse Turker Aras

摘要

Background

Impaired central neuropeptide production is implicated in polycystic ovary syndrome (PCOS).

Aim

This study aimed to determine whether plasma phoenixin-14, galanin (GAL), galanin-like peptide (GALP), and spexin levels in women with PCOS were altered compared to those in non-PCOS controls.

Methods

Sixty participants, including 30 patients diagnosed with PCOS and 30 healthy controls, were enrolled in this study. Phoenixin-14, GAL, GALP, and spexin levels were measured in plasma samples.

Results

Although plasma phoenixin-14 levels in the PCOS group were significantly higher than those in the control group, spexin and GAL levels were significantly lower. No significant intergroup differences were observed in plasma GALP levels (p = 0.442). To distinguish PCOS from healthy controls, the area under the receiver operating characteristic (ROC) curve (AUC) of phoenixin-14 was 0.798, that of spexin was 0.757, and that of GAL was 0.702 (p < 0.001, p < 0.001, and p = 0.003, respectively). The AUC of the combined diagnostic value of the three peptides for PCOS was 0.910 (95%CI: 0.808–0.968) (p < 0.001), indicating a good diagnostic value.

Conclusions

Plasma phoenixin-14, spexin, and GAL levels differed between patients with PCOS and controls. When combined, the three peptides exhibited better predictive performance than the individual peptides.